JPMorgan Chase & Co. Has $8.10 Million Holdings in Kyverna Therapeutics, Inc. (NASDAQ:KYTX)

JPMorgan Chase & Co. trimmed its holdings in shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Free Report) by 9.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,166,437 shares of the company's stock after selling 220,915 shares during the period. JPMorgan Chase & Co. owned about 5.02% of Kyverna Therapeutics worth $8,102,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. FMR LLC purchased a new stake in shares of Kyverna Therapeutics during the third quarter valued at approximately $33,000. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Kyverna Therapeutics during the fourth quarter valued at about $34,000. Corebridge Financial Inc. increased its holdings in Kyverna Therapeutics by 42.3% during the 4th quarter. Corebridge Financial Inc. now owns 12,811 shares of the company's stock worth $48,000 after purchasing an additional 3,810 shares during the last quarter. Rhumbline Advisers raised its position in shares of Kyverna Therapeutics by 31.1% in the 4th quarter. Rhumbline Advisers now owns 25,920 shares of the company's stock valued at $97,000 after purchasing an additional 6,153 shares in the last quarter. Finally, BNP Paribas Financial Markets boosted its stake in shares of Kyverna Therapeutics by 2,166.4% during the 3rd quarter. BNP Paribas Financial Markets now owns 27,197 shares of the company's stock valued at $133,000 after buying an additional 25,997 shares during the last quarter. 18.08% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

KYTX has been the subject of several recent analyst reports. HC Wainwright decreased their price objective on shares of Kyverna Therapeutics from $6.00 to $4.00 and set a "neutral" rating for the company in a report on Thursday, April 3rd. Morgan Stanley decreased their price objective on shares of Kyverna Therapeutics from $40.00 to $20.00 and set an "overweight" rating for the company in a report on Tuesday, April 1st. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, Kyverna Therapeutics has an average rating of "Buy" and a consensus target price of $18.33.

Kyverna Therapeutics Trading Up 1.6 %

NASDAQ:KYTX traded up $0.03 during mid-day trading on Friday, reaching $1.86. 286,269 shares of the stock were exchanged, compared to its average volume of 427,679. Kyverna Therapeutics, Inc. has a 1-year low of $1.78 and a 1-year high of $19.67. The firm has a market capitalization of $80.39 million, a PE ratio of -0.54 and a beta of 2.57. The business has a fifty day moving average price of $2.40 and a 200 day moving average price of $3.68.

Kyverna Therapeutics (NASDAQ:KYTX - Get Free Report) last posted its quarterly earnings results on Thursday, March 27th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.87) by ($0.01). On average, sell-side analysts forecast that Kyverna Therapeutics, Inc. will post -3.29 earnings per share for the current year.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.